nach oben

Erschienen in:

01.06.2012 | Clinical Trial Report

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl⁺ hematological malignancies

verfasst von: Prithviraj Bose, Edward B. Perkins, Connie Honeycut, Martha D. Wellons, Tammy Stefan, James W. Jacobberger, Emmanouil Kontopodis, Jan H. Beumer, Merrill J. Egorin, Chiyo K. Imamura, W. Douglas Figg Sr., Judith E. Karp, Omer N. Koc, Brenda W. Cooper, Selina M. Luger, A. Dimitrios Colevas, John D. Roberts, Steven Grant

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Imatinib is an inhibitor of the Bcr-Abl tyrosine kinase; however, resistance is common. Flavopiridol, a cyclin-dependent kinase (CDK) inhibitor, down-regulates short-lived anti-apoptotic proteins via inhibition of transcription. In preclinical studies, flavopiridol synergizes with imatinib to induce apoptosis. We investigated this novel combination regimen in patients with Bcr-Abl⁺ malignancies.

Methods

In a phase I dose-escalation study, imatinib was administered orally daily, and flavopiridol by 1 h intravenous infusion weekly for 3 weeks every 4 weeks. Adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute leukemia were eligible. Patients were divided into two strata based on peripheral blood and bone marrow blast counts. The primary objective was to identify the recommended phase II doses for the combination. Correlative pharmacokinetic and pharmacodynamic studies were also performed.

Results

A total of 21 patients received study treatment. Four dose levels were evaluated before the study was closed following the approval of the second-generation Bcr-Abl tyrosine kinase inhibitors (TKIs). Five patients responded, including four sustained responses. Four patients had stable disease. All but one responder, and all patients with stable disease had previously been treated with imatinib. One patient had a complete response sustained for 30 months. Changes in expression of phospho-Bcr/Abl, -Stat5, and Mcl-1 were monitored. No major pharmacokinetic interaction was observed.

Conclusions

This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.

Nur mit Berechtigung zugänglich

Deininger MWN, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356PubMed

O’Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004PubMedCrossRef

Fielding AK (2010) How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 116:3409–3417PubMedCrossRef

Clarke MF (2004) Chronic myelogenous leukemia—identifying the Hydra’s heads. N Engl J Med 351:634–636PubMedCrossRef

Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357:258–265PubMedCrossRef

Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172–187PubMedCrossRef

Goldman JM (2007) How I treat chronic myeloid leukemia in the imatinib era. Blood 110:2828–2837PubMedCrossRef

Dai Y, Grant S (2003) Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 3:362–370PubMedCrossRef

Blagosklonny MV (2004) Flavopiridol, an inhibitor of transcription. Cell Cycle 3:1537–1542PubMedCrossRef

10.

Shapiro GI (2004) Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10:4270s–4275sPubMedCrossRef

11.

Chao SH, Price DH (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793–31799PubMedCrossRef

12.

Grant S, Dent P (2004) Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what’s in a name? Mol Cancer Ther 3:873–875PubMed

13.

Senderowicz AM (2002) The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 7(suppl 3):12–19PubMedCrossRef

14.

Dai Y, Yu C, Singh V et al (2001) Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 61:5106–5115PubMed

15.

Yu C, Krystal G, Dent P, Grant S (2002) Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 8:2976–2984PubMed

16.

Simon R, Freidlin B, Rubinstein L et al (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147PubMedCrossRef

17.

Holkova B, Perkins EB, Ramakrishnan V et al (2011) Phase I trial of bortezomib (PS341; NSC681239) and alvocidib (flavopiridol; NSC649890) in patients with relapsed or refractory B-cell neoplasms. Clin Cancer Res 17(10):3388–3397PubMedCrossRef

18.

Carlesso N, Frank DA, Griffin JD (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183(3):811–820PubMedCrossRef

19.

Ilaria RL Jr, Van Etten RA (1996) P210 and P190 (BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271(49):31704–31710PubMedCrossRef

20.

Shuai K, Halpern J, ten Hoeve J et al (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13(2):247–254PubMed

21.

Jacobberger JW, Sramkoski RM, Frisa PS et al (2003) Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity. Cytometry A 54(2):75–88PubMedCrossRef

22.

Karp JE, Passaniti A, Gojo I et al (2005) Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 11(23):8403–8412PubMedCrossRef

23.

Tan AR, Yang X, Berman A et al (2004) Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 10(15):5038–5047PubMedCrossRef

24.

Senderowicz AM, Headlee D, Stinson SF et al (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986–2999PubMed

25.

Schwartz GK, Ilson D, Saltz L et al (2001) Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19:1985–1992PubMed

26.

Shapiro GI, Supko JG, Patterson A et al (2001) A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7:1590–1599PubMed

27.

Stadler WM, Vogelzang NJ, Amato R et al (2000) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium Study. J Clin Oncol 18:371–375PubMed

28.

Tan AR, Headlee D, Messman R et al (2002) Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 20:4074–4082PubMedCrossRef

29.

Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399–404PubMedCrossRef

30.

Rathkopf DE, Ilson DH, Yi S et al (2004) A phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer. Presented at the American society of clinical oncology gastrointestinal cancers symposium, San Francisco, CA, January 22–24, 2004 (abstract 67)

31.

Rathkopf DE, Fornier M, Shah MA et al (2004) A phase I dose-finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced, solid tumors. J Clin Oncol 2004(22):213s suppl; abstr 3072

32.

Shah MA, Kortmansky J, Motwani M et al (2005) A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 11:3836–3845PubMedCrossRef

33.

Lin TS, Blum KA, Fischer DB et al (2010) Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 28(3):418–423PubMedCrossRef

34.

Karp JE, Blackford A, Smith BD et al (2010) Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res 34(7):877–882PubMedCrossRef

35.

Karp JE, Smith BD, Resar LS et al (2011) Phase I and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117:3302–3310PubMedCrossRef

36.

Karp JE, Pagel JM, Smith BD et al (2010) Randomized phase II study of two schedules of flavopiridol (alvocidib, F) given as timed sequential therapy (TST) with Ara-C and mitoxantrone (FLAM) for adults with newly diagnosed, poor-risk acute myelogenous leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2010; 116 (Abstract 186)

37.

Peng B, Lloyd P, Schran H (2005) Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44(9):879–894PubMedCrossRef

38.

Deferme S, Van Gelder J, Augustijns P (2002) Inhibitory effect of fruit extracts on P-glycoprotein-related efflux carriers: an in vitro screening. J Pharm Pharmacol 54(9):1213–1219PubMedCrossRef

39.

Blum W, Klisovic MA, Phelps RB et al (2010) Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed and refractory acute leukemias. Haematologica 95(7):1098–1105PubMedCrossRef

40.

Houghton PJ, Germain GS, Harwood FC et al (2004) Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64(7):2333–2337PubMedCrossRef

41.

Robey RW, Medina-Pérez WY, Nishiyama K et al (2001) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7(1):145–152PubMed

42.

Nelson EA, Walker SR, Weisberg E et al (2011) The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117:3421–3429PubMedCrossRef

43.

Warsch W, Kollmann K, Eckelhart E et al (2011) High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 117:3409–3420PubMedCrossRef

44.

Dickson MA, Schwartz GK (2009) Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 16(2):36–43PubMed

45.

Moore AS, Blagg J, Linardopoulos S, Pearson AD (2010) Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 24(4):671–678PubMedCrossRef

Titel: Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
verfasst von: Prithviraj Bose
Edward B. Perkins
Connie Honeycut
Martha D. Wellons
Tammy Stefan
James W. Jacobberger
Emmanouil Kontopodis
Jan H. Beumer
Merrill J. Egorin
Chiyo K. Imamura
W. Douglas Figg Sr.
Judith E. Karp
Omer N. Koc
Brenda W. Cooper
Selina M. Luger
A. Dimitrios Colevas
John D. Roberts
Steven Grant
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 6/2012
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-1839-5

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl⁺ hematological malignancies

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2012

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib

Transient elevation of serum cystatin C concentrations during perioperative cisplatin-based chemotherapy in esophageal cancer patients

An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens

Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity

Ascorbic acid and healthy lymphocytes: a way to explain anticancer activity?

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie